Emerging therapeutic targets for soft tissue sarcoma

Current Oncology Reports

Volumn 13, Issue 4, 2011, Pages 350-358

  Smith, Jason L ^a   Riedel, Richard F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Molecular targets; Novel therapies; Soft tissue sarcoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CRIZOTINIB; CYCLIN DEPENDENT KINASE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GANITUMAB; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE; IFOSFAMIDE; IMATINIB; MONOCLONAL ANTIBODY R1507; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PROTEIN MDM2; RIDAFOROLIMUS; ROMIDEPSIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ADVANCED CANCER; ANGIOSARCOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; COCARCINOGENESIS; COLORECTAL CARCINOMA; CUTANEOUS T CELL LYMPHOMA; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE ASSOCIATION; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEMANGIOENDOTHELIOMA; HEMANGIOPERICYTOMA; HUMAN; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA;

EID: 80051670472     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0175-y     Document Type: Review

References (88)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. Epub 2010 Jul 7.
2. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2010 Oct 13. [Epub ahead of print].
3. DA Schoenfeld C Rosenbaum J Horton, et al. 1982 A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-d and cyclophosphamide for advanced sarcoma Cancer. 50 2757 62 7139566 10.1002/1097-0142(19821215)50:12<2757::AID- CNCR2820501211>3.0.CO;2-J 1:STN:280:DyaL3s%2FltVGltA%3D%3D (Pubitemid 13220781)
4. JH Edmonson LM Ryan RH Blum, et al. 1993 Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol. 11 7 1269 75 8315424 1:STN:280:DyaK3szgtFKlsg%3D%3D (Pubitemid 23199129)
5. A Santoro T Tursz H Mouridsen, et al. 1995 Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol. 13 7 1537 45 7602342 1:STN:280:DyaK2MzisFylug%3D%3D
6. K Antman J Crowley SP Balcerzak, et al. 1993 An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas J Clin Oncol. 11 7 1276 85 8315425 1:STN:280:DyaK3szgtFKlsw%3D%3D (Pubitemid 23199130)
7. ML Hensley JA Blessing R Mannel, et al. 2008 Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial Gynecol Oncol. 109 3 329 34 18534250 10.1016/j.ygyno.2008.03.010 1:CAS:528:DC%2BD1cXmvVKrsLw%3D (Pubitemid 351754961)
8. ML Hensley JA Blessing K Degeest, et al. 2008 Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecol Oncol. 109 3 323 8 18394689 10.1016/j.ygyno.2008.02.024 1:CAS:528:DC%2BD1cXmvVKrsL8%3D Epub 2008 Apr 18.
9. RG Maki JK Wathen SR Patel, et al. 2007 Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007, 25(19):2755-63. Erratum in J Clin Oncol. 25 24 3790 1:CAS:528:DC%2BD2sXhtlKjtL7E
10. M Schlemmer P Reichardt J Verweij, et al. 2008 Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group Eur J Cancer. 44 16 2433 6 18771914 10.1016/j.ejca.2008.07.037 1:CAS:528:DC%2BD1cXht12gtrnM Epub 2008 Sep 2
11. N Penel BN Bui JO Bay D Cupissol, et al. 2008 Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study J Clin Oncol. 26 32 5269 74 18809609 10.1200/JCO.2008.17.3146 1:CAS:528:DC%2BD1cXhsVyqsrbJ Epub 2008 Sep 22
12. S Sleijfer M Ouali M van Glabbeke, et al. 2010 Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer. 46 1 72 83 19853437 10.1016/j.ejca.2009.09.022 1:CAS:528: DC%2BD1MXhsFGrsbvF
13. JH Edmonson LM Ryan CI Falkson, et al. 2003 Phase II Study of Ifosfamide + Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group Sarcoma. 7 1 9 11 18521363 10.1080/1357714031000114156 1:CAS:528:DC%2BD3sXjt1ehu74%3D (Pubitemid 36577841)
14. KM Skubitz PA Haddad 2005 Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma Cancer. 104 2 361 6 15948172 10.1002/cncr.21140 1:CAS:528:DC%2BD2MXnslymu7o%3D (Pubitemid 40993264)
15. Ch van Kesteren MM de Vooght L López-Lázaro, et al. 2003 Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin Anticancer Drugs. 14 7 487 502 12960733 10.1097/00001813-200308000-00001 (Pubitemid 37083154)
16. M D'Incalci CM Galmarini 2010 A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther. 9 8 2157 63 20647340 10.1158/1535-7163.MCT- 10-0263 Epub 2010 Jul 20
17. PG Casali R Sanfilippo M D'Incalci 2010 Trabectedin therapy for sarcomas Curr Opin Oncol. 22 4 342 6 20489618 10.1097/CCO.0b013e32833aaac1
18. M D'Incalci D Brunelli E Marangon, et al. 2007 Modulation of gene transcription by natural products-a viable anticancer strategy Curr Pharm Des. 13 27 2744 50 17897020 10.2174/138161207781757097 (Pubitemid 350138965)
19. A Le Cesne JY Blay I Judson, et al. 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol. 23 3 576 84 15659504 10.1200/JCO.2005.01.180 (Pubitemid 46224235)
20. F Grosso RL Jones GD Demetri, et al. 2007 Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol. 8 7 595 602 17586092 10.1016/S1470-2045(07)70175-4 1:CAS:528:DC%2BD2sXnsFKkur0%3D (Pubitemid 46995623)
21. GD Demetri SP Chawla M von Mehren, et al. 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol. 27 25 4188 96 19652065 10.1200/JCO.2008.21.0088 1:CAS:528:DC%2BD1MXhtF2jtLrL
22. P Hingorani W Zhang S Piperdi, et al. 2009 Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma Cancer Chemother Pharmacol. 64 4 733 40 19224214 10.1007/s00280-008-0922-4 1:CAS:528:DC%2BD1MXptFCksL0%3D Epub 2009 Feb 18
23. Camacho, LH, Chawla, SP, Chua V, Abbadessa, G. et al. A phase I study of palifosfamide in combination with doxorubicin: Safety and preliminary efficacy [abstract 10577]. Presented at the 2009 ASCO Annual Meeting. Orlando, FL, USA; May 29-June 2, 2009.
24. Verschraegen CF, Chawla, SP, Mita MM, et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO) [abstract 10004]. Presented at the 2010 ASCO Annual Meeting. Chicago, IL, USA; June 4-8, 2010.
25. KU Patel SS Szabo VS Hernandez, et al. 2008 Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays Hum Pathol. 39 2 184 193 17950782 10.1016/j.humpath. 2007.06.009 1:CAS:528:DC%2BD1cXovFKqsQ%3D%3D
26. D Lemm LO Mügge T Mentzel K Höffken 2009 Current treatment options in dermatofibrosarcoma protuberans Cancer Res Clin Oncol. 135 5 653 65 10.1007/s00432-009-0550-3 Epub 2009 Feb 10
27. RP Dematteo KV Ballman CR Antonescu, et al. 2009 Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet. 373 9669 1097 104 19303137 10.1016/S0140-6736(09)60500-6 1:CAS:528:DC%2BD1MXjslOltro%3D Epub 2009 Mar 18
28. GD Demetri M von Mehren CD Blanke, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med. 347 7 472 80 12181401 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D (Pubitemid 34879334)
29. GD Demetri M von Mehren CR Antonescu, et al. 2010 NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors J Natl Compr Canc Netw. 8 Suppl 2 S1 41 20457867 1:CAS:528:DC%2BC3cXlvFOls7g%3D
30. CA Brady LD Attardi 2010 p53 at a glance J Cell Sci. 123 Pt 15 2527 32 20940128 10.1242/jcs.064501 1:CAS:528:DC%2BC3cXhtF2mt7fL
31. Wang H, Ma X, Ren S, Buolamwini JK, et al.: A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 2011, 10(1):69-79. Epub 2010 Nov 12.
32. PB Aleixo AA Hartmann IC Menezes, et al. 2009 Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours J Clin Pathol. 62 1127 1135 19946100 10.1136/jcp.2009.070201 1:STN:280:DC%2BD1MjovFWkug%3D%3D
33. A Mariño-Enríquez CD Fletcher 2009 Dal Cin P, et al.: Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria J Clin Pathol. 62 12 1127 35 10.1136/jcp.2009.070201
34. KI Pishas F Al-Ejeh I Zinonos, et al. 2011 Nutlin-3a is a potential therapeutic for Ewing Sarcoma Clin Cancer Res. 17 3 494 504 21098696 10.1158/1078-0432.CCR-10-1587 1:CAS:528:DC%2BC3MXhsVersbo%3D Epub 2010 Nov 23
35. Z Hélias-Rodzewicz F Pédeutour JM Coindre, et al. 2009 Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma Genes Chromosom Cancer. 48 11 943 52 19626636 10.1002/gcc.20696
36. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med. 350 23 2335 42 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
37. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med. 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
38. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet. 370 9605 2103 2111 18156031 10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)
39. EE Pakos AC Goussia PG Tsekeris, et al. 2005 Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas Anticancer Res. 25 3591 3596 16101185 1:CAS:528:DC%2BD2MXps1Kgurs%3D (Pubitemid 41105246)
40. MS Park V Ravi DM Araujo 2010 Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor Curr Opin Oncol. 22 4 351 5 20485168 10.1097/CCO.0b013e32833aaad4 1:CAS:528:DC%2BC3cXntF2js74%3D
41. S Sleijfer I Ray-Coquard Z Papai, et al. 2009 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 27 19 3126 32 19451427 10.1200/JCO.2008.21.3223 1:CAS:528: DC%2BD1MXhtFWitb3P
42. S George P Merriam RG Maki, et al. 2009 Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol. 27 19 3154 60 19451429 10.1200/JCO.2008.20.9890 1:CAS:528: DC%2BD1MXhtFWitb3E Epub 2009 May 18
43. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011 Jan 17. [Epub ahead of print].
44. RG Maki DR D'Adamo ML Keohan, et al. 2009 Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol. 27 19 3133 40 19451436 10.1200/JCO.2008.20.4495 1:CAS:528:DC%2BD1MXhtFWitb3J Epub 2009 May 18.
45. E Fox R Aplenc R Bagatell, et al. 2010 A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors J Clin Oncol. 28 35 5174 81 21060028 10.1200/JCO.2010.30.9674 1:CAS:528:DC%2BC3MXhtlaktLw%3D Epub 2010 Nov 8
46. Gardner K, Judson I, Leahy M. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma [abstract 10523]. Presented at the 2009 ASCO Annual Meeting. Orlando, FL, USA; May 29-June 2, 2009.
47. Agulnik M, Okuno SH, Von Mehren M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma [abstract 10522]. Presented at the 2009 ASCO Annual Meeting. Orlando, FL, USA; May 29-June 2, 2009.
48. CK Fuller JA Charlson SK Dankle, et al. 2010 Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy J Am Acad Dermatol. 63 4 e83 4 20846560 10.1016/j.jaad.2009.09.035
49. A Rosen S Thimon D Ternant, et al. 2010 Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face Br J Dermatol. 163 1 225 7 20394623 1:STN:280:DC%2BC3cnosFGksw%3D%3D Epub 2010 Apr 12
50. Park MS, Patel SR, Ludwig JA, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor [abstract 10512]. Presented at the 2008 ASCO Annual Meeting. Chicago, IL, USA; May 30-June 3, 2008.
51. SW Morris MN Kirstein MB Valentine, et al. 1994 Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science. 263 1281 1284 8122112 10.1126/science.8122112 1:CAS:528:DyaK2cXis1aks7Y%3D (Pubitemid 24107549)
52. RH Palmer E Vernersson C Grabbe, et al. 2009 Anaplastic lymphoma kinase: signalling in development and disease Biochem J. 420 3 345 61 19459784 10.1042/BJ20090387 1:CAS:528:DC%2BD1MXmtlOls7c%3D
53. M Ladanyi 2000 Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms Am J Pathol. 157 2 341 5 10934137 10.1016/S0002-9440(10)64545-2 1:CAS:528:DC%2BD3cXlvFyrurw%3D (Pubitemid 30626900)
54. JE Butrynski DR D'Adamo JL Hornick, et al. 2010 Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N Engl J Med. 363 18 1727 33 20979472 10.1056/NEJMoa1007056 1:CAS:528:DC%2BC3cXhtlKitL%2FI
55. EL Kwak Y-J Bang DR Camidge, et al. 2010 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med. 363 1693 1703 20979469 10.1056/NEJMoa1006448 1:CAS:528:DC%2BC3cXhtlKitL%2FO
56. SH Ou L Bazhenova DR Camidge, et al. 2010 Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer J Thorac Oncol. 5 12 2044 6 21102269 10.1097/JTO.0b013e318200f9ff
57. A Ganesan L Nolan SJ Crabb, et al. 2009 Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery Curr Cancer Drug Targets. 9 8 963 81 20025605 10.2174/156800909790192428 1:CAS:528: DC%2BC3cXhslKnsLc%3D
58. L Ellis R Pili 2010 Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies Pharmaceuticals (Basel). 3 8 2411 2469
59. EA Olsen YH Kim TM Kuzel, et al. 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol. 25 21 3109 15 17577020 10.1200/JCO.2006.10.2434 1:CAS:528:DC%2BD2sXptlGrtrs%3D Epub 2007 Jun 18 (Pubitemid 47218059)
60. RL Piekarz R Frye M Turner, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol. 27 32 5410 7 19826128 10.1200/JCO.2008.21.6150 1:CAS:528:DC%2BD1MXhsFKkt7vO Epub 2009 Oct 13
61. T Ito M Ouchida Y Morimoto, et al. 2005 Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo Cancer Lett. 224 2 311 9 15914281 10.1016/j.canlet.2004.10.030 1:CAS:528:DC%2BD2MXks1Ggt7w%3D Epub 2004 Dec 8 (Pubitemid 40725851)
62. Kwan J, Terry S, Liu M, et al. Effect of depsipeptide (NSC 630176), a histone deacetylase inhibitor, on human synovial sarcoma in vitro [abstract 9039]. Presented at the 2005 ASCO Annual Meeting. Orlando, FL, USA; May 13-17, 2005.
63. L Su H Cheng AV Sampaio, et al. 2010 EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor Oncogene. 29 30 4352 61 20514024 10.1038/onc.2010.204 1:CAS:528:DC%2BC3cXms1ynur4%3D Epub 2010 May 31
64. M Wachtel BW Schäfer 2010 Targets for cancer therapy in childhood sarcomas Cancer Treat Rev. 36 4 318 27 20223596 10.1016/j.ctrv.2010.02.007 1:CAS:528:DC%2BC3cXmtlyhsbo%3D Epub 2010 Mar 12
65. S Bauer LK Yu GD Demetri, et al. 2006 Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor Cancer Res. 66 18 9153 61 16982758 10.1158/0008-5472.CAN-06-0165 1:CAS:528:DC%2BD28Xps1aiu74%3D (Pubitemid 44521135)
66. RG Maki 2010 Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer J Clin Oncol. 28 33 4985 95 20975071 10.1200/JCO.2009.27.5040 1:CAS:528:DC%2BC3MXisFCnug%3D%3D Epub 2010 Oct 25
67. D Olmos DS Tan RL Jones, et al. 2010 Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside Cancer J. 16 3 183 94 20526094 10.1097/PPO.0b013e3181dbebf9 1:CAS:528: DC%2BC3cXovV2rt74%3D
68. A Prieur F Tirode P Cohen, et al. 2004 EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3 Mol Cell Biol. 24 7275 7283 15282325 10.1128/MCB.24.16.7275-7283.2004 1:CAS:528: DC%2BD2cXmtlOjtLs%3D (Pubitemid 39014452)
69. MA Pantaleo A Astolfi M Di Battista, et al. 2009 Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target Int J Cancer. 125 12 2991 4 19672856 10.1002/ijc.24595 1:CAS:528:DC%2BD1MXhtlSqsLrE
70. Patel S, Pappo A, Crowley J, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas [abstract 10001]. Presented at the 2010 ASCO Annual Meeting. Chicago, IL, USA; June 4-8, 2010.
71. Pappo AS, Patel S, Crowley J, et al. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study [abstract 10000]. Presented at the 2010 ASCO Annual Meeting. Chicago, IL, USA; June 4-8, 2010.
72. AW Tolcher J Sarantopoulos A Patnaik, et al. 2009 Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J Clin Oncol. 27 34 5800 7 19786654 10.1200/JCO.2009.23.6745 1:CAS:528:DC%2BC3cXhtVWitr8%3D Epub 2009 Sep 28
73. ES Kim 2009 Salgia: MET Pathway as a Therapeutic Target J Thorac Oncol. 4 4 444 447 19333071 10.1097/JTO.0b013e31819d6f91
74. CF Gao Q Xie YW Zhang, et al. 2009 Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma Mol Cancer Ther. 8 10 2803 10 19825800 10.1158/1535-7163.MCT-09-0125 1:CAS:528:DC%2BD1MXht1Cqur7M
75. K Nakamura F Abarzua A Hongo, et al. 2010 Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma Int J Oncol. 37 3 605 14 20664929 10.3892/ijo-00000709 1:CAS:528:DC%2BC3cXhtFSkt73N
76. IJ Davis AW McFadden Y Zhang, et al. 2010 Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma Cancer Res. 70 2 639 45 20068147 10.1158/0008-5472.CAN-09-1121 1:CAS:528:DC%2BC3cXltlWqsQ%3D%3D Epub 2010 Jan 12
77. R Zoncu A Efeyan DM Sabatini 2011 mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol. 12 1 21 35 21157483 10.1038/nrm3025 1:CAS:528:DC%2BC3cXhsFGqsbnK Epub 2010 Dec 15
78. JY Blay 2011 Updating progress in sarcoma therapy with mTOR inhibitors Ann Oncol. 22 2 280 7 20591820 10.1093/annonc/mdq307 This is a concise overview of the relevance of the mTOR pathway as a clinical target in sarcoma therapy. Epub 2010 June 29
79. DD Sarbassov DA Guertin SM Ali, et al. 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science. 307 5712 1098 1101 15718470 10.1126/science.1106148 1:CAS:528:DC%2BD2MXhtlSrtbY%3D (Pubitemid 40262113)
80. AP Bhatt PM Bhende SH Sin, et al. 2010 Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood. 115 22 4455 63 20299510 10.1182/blood-2009-10-251082 1:CAS:528:DC%2BC3cXnsFKnt7c%3D Epub 2010 Mar 18
81. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma N Eng J Med. 356 2 2271 81 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
82. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet. 372 9637 449 456 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
83. MM Mita AC Mita QS Chu, et al. 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol. 26 3 361 7 18202410 10.1200/JCO.2007.12.0345 1:CAS:528:DC%2BD1cXitVGntLk%3D (Pubitemid 351171685)
84. Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial [abstract 10076]. Presented at the 2007 ASCO Annual Meeting. Chicago, IL, USA; June 1-5, 2007.
85. Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669) [abstract 3509]. Presented at the 2008 ASCO Annual Meeting. Chicago, IL, USA; May 30-June 3, 2008.
86. J Barretina BS Taylor S Banerji, et al. 2010 Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat Genet. 42 8 715 21 20601955 10.1038/ng.619 1:CAS:528:DC%2BC3cXotlWktLY%3D Sequenced protein-coding sequences from tumor and control DNA to highlight histology-specific mutations, potential therapeutic targets, and molecular predictors of response to pathway-directed therapy in STS. Epub 2010 Jul 4
87. Peng T, Zhang P, Liu J, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2010 Nov 8. [Epub ahead of print].
88. L Gibault G Pérot F Chibon, et al. 2011 New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics J Pathol. 223 1 64 71 21125665 10.1002/path.2787 1:CAS:528:DC%2BC3MXht1GnsLY%3D Utilized comparative genomic hybridization and transcriptome analysis to identify dysregulated pathway activation in the poorly molecularly characterized pleomorphic undifferentiated STS. Epub 2010 Oct 25